Biocon gets nod to raise $250 million via NCDs

15 Nov 2022 Evaluate

Biocon has received an approval for issuance of Redeemable, Non-Convertible Debentures (NCDs) aggregating up to INR equivalent of $250 million on private placement basis. It has also received an approval for issuance of Commercial Paper up to INR equivalent of $275 million on private placement basis. The Board of Directors at its meeting held on November 14, 2022, inter alia, has approved the same.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×